Progyny, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PGNY research report →
Range $30 – $40
Price Chart
About the company
Progyny, Inc. functions as a benefits management corporation, dedicated to providing specialized solutions for fertility and broader family-building initiatives to employers throughout the United States. Its core fertility offering is characterized by a distinctive benefits plan architecture, paired with personalized, white-glove member support services and access to a meticulously chosen network of top-tier fertility specialists.
- CEO
- Pete Anevski
- IPO
- 2019
- Employees
- 846
- HQ
- New York City, NY, US
Get TickerSpark's AI analysis on PGNY
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $2.63B
- P/E
- 31.92
- Fwd P/E
- 27.11
- PEG
- 0.43
- P/S
- 2.02
- P/B
- 6.76
- EV/EBITDA
- 18.58
- Div Yield
- 0.00%
- Gross Margin
- 24.87%
- Op Margin
- 9.40%
- Net Margin
- 6.80%
- ROE
- 19.98%
- ROIC
- 19.86%
Latest fiscal year · YoY change
- Revenue
- $1.29B+10.4%
- Gross Profit
- $304.48M+20.2%
- Op Income
- $85.28M
- Net Income
- $58.52M+7.7%
- EPS
- $0.68+15.3%
- OCF Growth
- +17.4%
- FCF Growth
- +10.4%
- 52W High
- $37.21
- 52W Low
- $16.10
- 50D MA
- $29.24
- 200D MA
- $25.08
- Beta
- 0.97
- RSI (14)
- 67
- Avg Volume
- 1.10M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Progyny delivered record third-quarter revenue and profitability, raised the midpoint of full-year guidance, and said its strongest selling season ever positions it well for 2027.· November 4, 2026
- Record Q3 revenue and profitability, with revenue above the midpoint of guidance and record third-quarter results.
- Selling season was exceptionally strong: 1.3 million new covered lives and over 85 new clients, with near 100% retention of the existing base.
- Management said member engagement remains healthy and Q4 visibility is good, supporting a raised full-year outlook.
- Margins remained healthy despite continued investment, aided by gross margin expansion and strong cash conversion.
- Share repurchases remained meaningful, with nearly 3 million shares bought back in Q3 and about $51 million still available under the current authorization.
Third-quarter revenue was above the midpoint of guidance and increased nearly 9% year over year; management also said revenue rose 11% over the first 9 months excluding a large former client under a transition-of-care agreement. Gross margin expanded by 130 basis points year over year, while adjusted EBITDA margin was modestly lower than last year but still consistent on a trailing-12-month basis at 17.1%. Operating cash flow was more than $56 million in the quarter and $207 million on a trailing-12-month basis, and DSO ended just under 66 days, nearly 7 days lower than a year ago. For full year 2026, revenue is now expected to be $1.365 billion to $1.385 billion, adjusted EBITDA $235 million to $240 million, net income $107 million to $110.6 million, earnings per diluted share of $1.30 to $1.35, and adjusted EPS of $2.09 to $2.13. Fourth-quarter revenue is guided to $344.7 million to $364.7 million, adjusted EBITDA to $57.9 million to $62.9 million, and EPS to $0.36 to $0.41, with adjusted EPS of $0.53 to $0.58.
Pete Anevski framed the quarter as evidence of strong market demand and differentiated execution, saying Progyny delivered a record selling season and is entering 2027 with its strongest sales momentum ever. He emphasized that employers are prioritizing family-building and women’s health benefits because of rising healthcare costs and the need for better outcomes and member experience, and said Progyny’s track record continues to stand out versus alternatives. He also highlighted broad-based wins across industries and client sizes, near 100% retention, and continued expansion opportunities within the existing base.
Mark Livingston focused on the financial quality of the quarter: revenue growth, 130 basis points of gross margin expansion, and disciplined cash generation. He said adjusted EBITDA margin was 17.1% on a trailing-12-month basis, CapEx year-to-date was about $9 million above last year but still around 2% of revenue, and the company continued to exceed its 75% adjusted EBITDA-to-operating-cash-flow conversion target. He also noted more than $56 million of operating cash flow in the quarter, $196 million in cash and marketable securities, no debt, and nearly 3 million shares repurchased for about $83 million in Q3 under the current authorization.
Analysts pressed on the economics of a large public-sector client, and management said the margin profile should be consistent with the business overall, while utilization for that population was underwritten slightly lower than normal. Questions also focused on whether 2027 could bring margin expansion; management said investments are still expected to taper through 2027, but detailed 2027 guidance will come later. Other topics included competitive conversions, the Cigna partnership, eligibility-file completion, and utilization trends; management said competition remains active but rationalizing, the Cigna relationship is helping drive positive activity, eligibility files should be in place for more than half of lives by year-end, and utilization is tracking within expected ranges.
The bull case from the call is that Progyny is still winning share in a tough market: it added 1.3 million covered lives, more than 85 clients, and kept retention near 100%. Management also pointed to broad demand from employers, strong pipeline momentum for 2027, continued cash generation, and room for investment to moderate over time. If that plays out, the combination of growth, margin discipline, and buybacks could remain attractive.
The main risks discussed were that utilization can fluctuate, some of the new lives launch later in 2027, and the company is still in an investment phase that could limit near-term margin expansion. Management also acknowledged that the competitive environment is active, even if it is rationalizing, and that some of the recent selling-season benefits came from competitor takeaways rather than purely organic new demand. In addition, Q4 and 2027 results still depend on engagement and utilization patterns that management said they will know more about later.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 91.2%
- Shares Outstanding
- 73.65M
- Float Shares
- 67.18M
of shares held by institutions
318 13F filers
Buy/sell ratio 0.38. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for PGNY, newest first.
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 12.02M | ▲ 421.64K |
| Vanguard Group Inc | 9.63M | ▼ 472.76K |
| Fmr LLC | 7.19M | ▲ 186.88K |
| Vanguard Portfolio Management LLC | 5.54M | ▲ 522.02K |
| Vanguard Capital Management LLC | 3.25M | ▲ 36.50K |
| State Street Corp | 3.15M | ▲ 122.14K |
| Ameriprise Financial Inc | 2.76M | ▼ 61.82K |
| American Century Companies Inc | 2.58M | ▲ 1.81M |
| Geode Capital Management, LLC | 2.50M | ▲ 531.39K |
| Citadel Advisors LLC | 1.79M | ▲ 1.79M |
| Dimensional Fund Advisors LP | 1.77M | ▲ 85.22K |
| Fort Washington Investment Advisors Inc | 1.64M | ▼ 911.79K |
Held by 429 ETFs
Biggest fund positions in PGNY by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 11, 26 | Clapp Geoffrey | sell | 774 |
| Nov 10, 26 | Anevski Peter | other | 185,134 |
| Nov 10, 26 | Anevski Peter | sell | 120,213 |
| Nov 10, 26 | Anevski Peter | sell | 64,921 |
| Nov 10, 26 | Anevski Peter | sell | 33,437 |
| Nov 10, 26 | Anevski Peter | sell | 18,059 |
| Nov 10, 26 | Anevski Peter | other | 185,134 |
| Nov 10, 26 | Schlanger David J | other | 35,392 |
| Nov 10, 26 | Schlanger David J | sell | 35,392 |
| Nov 10, 26 | Schlanger David J | other | 35,392 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our PGNY coverage
Recent articles, reports, and earnings notes.
No research on PGNY yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PGNY report →5 Relative Price Strength Stocks to Tap Amid S&P 500 Weakness
zacks.com · Nov 20
Progyny (PGNY) Upgraded to Strong Buy: What Does It Mean for the Stock?
zacks.com · Nov 19
Progyny, Inc. (PGNY) Hits Fresh High: Is There Still Room to Run?
zacks.com · Nov 17
Progyny (PGNY) Is Up 3.85% in One Week: What You Should Know
zacks.com · Nov 16
Progyny: 3 Key Takeaways for Long-Term Investors
fool.com · Nov 10
Progyny (NASDAQ:PGNY) Reaches New 12-Month High After Earnings Beat
defenseworld.net · Nov 6
Progyny Q3 Earnings Call Highlights
marketbeat.com · Nov 5
Progyny, Inc. (PGNY) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 4
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.